{"id":35646,"date":"2024-04-17T12:48:33","date_gmt":"2024-04-17T10:48:33","guid":{"rendered":"https:\/\/www.abcsg.org\/?p=35646"},"modified":"2024-04-17T14:24:52","modified_gmt":"2024-04-17T12:24:52","slug":"current-big-newsletter-reports-on-the-abcsg-63-erika-trial","status":"publish","type":"post","link":"https:\/\/www.abcsg.org\/en\/current-big-newsletter-reports-on-the-abcsg-63-erika-trial\/","title":{"rendered":"Latest Big-Newsletter reports on the ABCSG 63 \/ ERIKA Trial"},"content":{"rendered":"

ABCSG 63 \/ ERIKA (Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer) trial to start study recruitment in Q2 2024!<\/p>\n

ABCSG 63 is an innovative, investigator-initiated trial in its final set-up phase, to be conducted in Austria and Germany under the academic sponsorship of ABCSG, and at approximately 18 trial sites with the recruitment target of 120 patients.<\/p>\n

It is designed as an open label, two-arm, two-step, randomized, phase II study in endocrine-responsive HER-2 negative early breast cancer patients. The present study plans to evaluate the therapeutic potential and the safety of a combination of the orally available SERD elacestrant and the CDK4\/6 inhibitor ribociclib. The primary study endpoint is defined as the proportion of the PEPI score of 0 at the time of surgery.<\/p>\n

Given the exciting study design, ABCSG and the study\u2019s collaborative partners are eager to initiate this new research project, once again leaving a strong academic footprint in the current clinical trial landscape for the benefit of breast cancer patients.<\/p>\n

Download Article<\/a><\/p>\n

Download BIG-Newsletter \u201eResearch in Focus\u201c April 2024 \u2013 issue n\u00b020<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

ABCSG 63 \/ ERIKA (Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer) trial to start study recruitment in Q2 2024! ABCSG 63 is an innovative, investigator-initiated trial in its final set-up phase, to be conducted in Austria and Germany under the academic sponsorship of ABCSG, and at approximately 18 trial sites with the recruitment […]<\/p>\n","protected":false},"author":1,"featured_media":35644,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[505],"tags":[581],"class_list":["post-35646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-abcsg-63-en"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-27 21:59:33","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/35646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=35646"}],"version-history":[{"count":4,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/35646\/revisions"}],"predecessor-version":[{"id":35654,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/posts\/35646\/revisions\/35654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media\/35644"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=35646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/categories?post=35646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=35646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}